Compare Revvity Inc (RVTY) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs SOLAI Limited — how do they compare? Revvity Inc trades at $124.14 (market cap $14.18B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: Revvity Inc is far larger — about 849.6× SOLAI Limited's market cap, and Revvity Inc pays a 0.22% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| RVTY | SLAI | |
|---|---|---|
Market Cap | $14.18B | $16.69M |
Sector | Technology | Technology |
52-Week High | $130.94 | $21.63 |
52-Week Low | $82.26 | $2.74 |
Enterprise Value | $16.50B | $16.33M |
Dividend Yield | 0.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
SLAI trades at $3.72 with no recent price movement, showing technical bullish signals despite fundamental challenges. The company reported negative financial metrics including -$33.88M net income and -134.63% net margin for 2025, though it beat Q2 2025 EPS expectations. Recent corporate actions include a 7:1 reverse stock split effective July 2026 and a NYSE delisting notice, creating significant uncertainty for investors.
The outlook remains highly speculative with substantial operational risks offset by low valuation multiples. Investment opportunity exists only for risk-tolerant investors betting on the AI infrastructure turnaround, while delisting proceedings and persistent losses present severe downside risks requiring careful monitoring of corporate developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
